- Glaukos (NYSE:GKOS) announces positive results from a multiyear single-site study evaluating the iStent inject Trabecular Micro-Bypass System, combined with cataract surgery, in glaucoma patients. The data were just published in the journal Ophthalmology and Therapy.
- After three years of follow-up, treated patients achieved a 37% reduction in mean intraocular pressure while mean medication burder dropped 68%.
- 93% of treated patients were able to reduce their medications. 54% of eyes were medication-free.